Literature DB >> 10990474

Who's afraid of Thomas Bayes?

R J Lilford1, D Braunholtz.   

Abstract

Sometimes direct evidence is so strong that a prescription for practice is decreed. Usually, things are not that simple-leaving aside the possibility that important trade offs may be involved, direct comparative data may be imprecise (especially in crucial sub-groups) or subject to possible bias, or there may be no direct comparative evidence; but still decisions have to be made. In these circumstances, indirect evidence-the plausibility of effects-enters the frame. But how should we describe the extent of plausibility and, having done so, how can this be integrated with any direct evidence that might exist. Also, how can allowance be made in a transparent (that is, explicit) way for perceptions of the size of bias in the direct evidence. Enter the Reverend Thomas Bayes; plausibility (however derived-laboratory experiment, qualitative study or just "experience") is captured numerically as degrees of belief ("prior" to the direct data) and updated (by the direct evidence) to yield "posterior" probabilities for use in decision making. The mathematical model used for this purpose must explicitly take account of assumptions about bias in the direct data. This paradigm bridges theory and practice, and provides the intellectual scaffold for those who recognise that (numerically definable) probabilities, and values (also numerically definable) underlie decisions, but who also realise that subjectivity is ineluctable in science.

Mesh:

Year:  2000        PMID: 10990474      PMCID: PMC1731566          DOI: 10.1136/jech.54.10.731

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  17 in total

Review 1.  Trials and fast changing technologies: the case for tracker studies.

Authors:  R J Lilford; D A Braunholtz; R Greenhalgh; S J Edwards
Journal:  BMJ       Date:  2000-01-01

2.  Commissioning health services research: an iterative method.

Authors:  R Lilford; R Jecock; H Shaw; J Chard; B Morrison
Journal:  J Health Serv Res Policy       Date:  1999-07

Review 3.  Decision analysis in medicine.

Authors:  J G Thornton; R J Lilford; N Johnson
Journal:  BMJ       Date:  1992-04-25

Review 4.  Preterm breech babies and randomised trials of rare conditions.

Authors:  J G Thornton; R J Lilford
Journal:  Br J Obstet Gynaecol       Date:  1996-07

5.  Optimal sample size for a series of pilot trials of new agents.

Authors:  T J Yao; C B Begg; P O Livingston
Journal:  Biometrics       Date:  1996-09       Impact factor: 2.571

6.  Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994.

Authors:  P A Crowley
Journal:  Am J Obstet Gynecol       Date:  1995-07       Impact factor: 8.661

7.  Case management: a dubious practice.

Authors:  M Marshall
Journal:  BMJ       Date:  1996-03-02

8.  Equipoise and the ethics of randomization.

Authors:  R J Lilford; J Jackson
Journal:  J R Soc Med       Date:  1995-10       Impact factor: 5.344

9.  Statistical ward rounds--5.

Authors:  D Mainland
Journal:  Clin Pharmacol Ther       Date:  1967 Sep-Oct       Impact factor: 6.875

10.  Investigating a sequence of randomized phase II trials to discover promising treatments.

Authors:  N Strauss; R Simon
Journal:  Stat Med       Date:  1995-07-15       Impact factor: 2.373

View more
  3 in total

1.  The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.

Authors:  Ben A van Hout; Dennis D Gagnon; Pauline McNulty; Anthony O'Hagan
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Bayes' theorem: a negative example of a RCT on grommets in children with glue ear.

Authors:  Maroeska M Rovers; Gert Jan van der Wilt; Sjoukje van der Bij; Huub Straatman; Koen Ingels; Gerhard A Zielhuis
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

Review 3.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.